SmartGuard™ is the exclusive technology from Medtronic that mimics some of the functions of a healthy pancreas. Our latest version of SmartGuard™ technology with the MiniMed™ 670G System takes on more tasks of diabetes management than ever before, so you don't have to.
The MiniMed™ 670G system offers SmartGuard™ technology that automatically adjusts insulin delivery every 5 minutes based on your glucose levels to help keep you in a healthy range. More time in range may mean better glucose control with fewer highs and lows, so you can feel healthy and confident focussing on your day, not on your diabetes.
What are the benefits of SmartGuard™ Auto Mode? 2,3,4
highs & lows 1
in healthy range 1 2 3
management 2 3
More freedom to
focus on your day 2 3
glucose control 4
to manage diabetes 5
"I never thought that in my lifetime I would see this type of freedom from diabetes. I no longer have to think about it every minute of every day.”
MiniMed™ 670G System user5
How does SmartGuard™ Auto Mode work?
Your insulin needs vary throughout the day. Traditional pump therapy delivers pre-programmed, fixed basal rates.
As your insulin needs vary throughout the day, it can be very challenging to predict and match unique basal
requirements that are changing on a daily basis.
SmartGuardTM Auto Mode constantly adapts to your real- time glucose needs and may deliver very different basal
rates each day and night – helping you stay in a healthy glucose range2 3
You may be interested in
MiniMed 670G™ System
The world's first self-adjusting insulin pump system.
The only technology that mimics some
of the functions of a healthy pancreas.
Many people find it a challenge to keep HbA1c
low in target range without increasing the risk of
- Iturralde E, et all. The Diabetes Educator. 2017; 43(2):223 – 232
- Bergenstal, RM, et al. Jama. 2016; 316 (13): 1407 – 1408
- Garg SK, et al. Diabetes Technol Ther. 2017 Mar;19(3):155-163
- Data on file. MiniMed 670G user experience survey, period Jun 2017 - Jan 2018, n=13.571
- Data on file. Survey of customer training phase patients.
- Gopalakrishnan S, et al. Diabetes Technol Ther. 2018 Feb;20 (S1): ATTD8-0240
- Chen J, et al. Diabetes Technology Meeting 2017. Journal of Diabetes Science and Technology, vol. 12, 2: pp. 426-532 (A10)